JP2003519102A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003519102A5 JP2003519102A5 JP2001541509A JP2001541509A JP2003519102A5 JP 2003519102 A5 JP2003519102 A5 JP 2003519102A5 JP 2001541509 A JP2001541509 A JP 2001541509A JP 2001541509 A JP2001541509 A JP 2001541509A JP 2003519102 A5 JP2003519102 A5 JP 2003519102A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- embedded image
- pharmaceutical composition
- treating
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 111
- 238000000034 method Methods 0.000 description 46
- 239000008194 pharmaceutical composition Substances 0.000 description 40
- -1 2- (methylaminocarbonylamino) -cyclohexyl Chemical group 0.000 description 37
- 102000009346 Adenosine receptors Human genes 0.000 description 24
- 108050000203 Adenosine receptors Proteins 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 125000000217 alkyl group Chemical group 0.000 description 17
- 229940002612 prodrug Drugs 0.000 description 17
- 239000000651 prodrug Substances 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 125000000547 substituted alkyl group Chemical group 0.000 description 8
- 0 CC(*)(C(OC)=O)NCc1cc2c(N3[C@](CO)CCC3)nc(-c3ccccc3)nc2[n]1 Chemical compound CC(*)(C(OC)=O)NCc1cc2c(N3[C@](CO)CCC3)nc(-c3ccccc3)nc2[n]1 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- 229910052717 sulfur Chemical group 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 4
- 201000010105 allergic rhinitis Diseases 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940113601 irrigation solution Drugs 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000011479 upper respiratory tract disease Diseases 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- IWCPLYWOMNSGKK-UHFFFAOYSA-N C(C1)NCCN1c1c(cc(-c2ccccc2)[nH]2)c2nc(-c2ccncc2)n1 Chemical compound C(C1)NCCN1c1c(cc(-c2ccccc2)[nH]2)c2nc(-c2ccncc2)n1 IWCPLYWOMNSGKK-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- NDHVCPFGQGUGDY-UHFFFAOYSA-N NC(CC(CC1)CN1c1c(cc(COc2cc(Cl)ccc2)[nH]2)c2nc(-c2ccccc2)n1)=O Chemical compound NC(CC(CC1)CN1c1c(cc(COc2cc(Cl)ccc2)[nH]2)c2nc(-c2ccccc2)n1)=O NDHVCPFGQGUGDY-UHFFFAOYSA-N 0.000 description 1
- NDHVCPFGQGUGDY-MRXNPFEDSA-N NC(C[C@@H](CC1)CN1c1c(cc(COc2cccc(Cl)c2)[nH]2)c2nc(-c2ccccc2)n1)=O Chemical compound NC(C[C@@H](CC1)CN1c1c(cc(COc2cccc(Cl)c2)[nH]2)c2nc(-c2ccccc2)n1)=O NDHVCPFGQGUGDY-MRXNPFEDSA-N 0.000 description 1
- QSTCWPQNBHCQSO-UHFFFAOYSA-O OC(CC1)CC1Nc1c(C=C[NH2+]2)c2nc(-c2ccccc2)n1 Chemical compound OC(CC1)CC1Nc1c(C=C[NH2+]2)c2nc(-c2ccccc2)n1 QSTCWPQNBHCQSO-UHFFFAOYSA-O 0.000 description 1
- ZKRMYQYRVJLFNY-MRXNPFEDSA-N OC(C[C@@H](CC1)CN1c1c(cc(COC2=CCCC(Cl)=C2)[nH]2)c2nc(-c2ccccc2)n1)=O Chemical compound OC(C[C@@H](CC1)CN1c1c(cc(COC2=CCCC(Cl)=C2)[nH]2)c2nc(-c2ccccc2)n1)=O ZKRMYQYRVJLFNY-MRXNPFEDSA-N 0.000 description 1
- HLMCALUKDRNUQT-VXGBXAGGSA-N OC[C@@H](C[C@H](C1)O)N1c1c(cc[nH]2)c2nc(-c2ccncc2)n1 Chemical compound OC[C@@H](C[C@H](C1)O)N1c1c(cc[nH]2)c2nc(-c2ccncc2)n1 HLMCALUKDRNUQT-VXGBXAGGSA-N 0.000 description 1
- YEGQZWNGCOHAGA-KRWDZBQOSA-N O[C@@H](CC1)CN1c1c(cc(-c2ccccc2)[nH]2)c2nc(-c2ccccc2)n1 Chemical compound O[C@@H](CC1)CN1c1c(cc(-c2ccccc2)[nH]2)c2nc(-c2ccccc2)n1 YEGQZWNGCOHAGA-KRWDZBQOSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000035176 regulation of the force of heart contraction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45425499A | 1999-12-02 | 1999-12-02 | |
| US09/454,074 | 1999-12-02 | ||
| US09/454,254 | 1999-12-02 | ||
| US09/454,074 US6878716B1 (en) | 1998-06-02 | 1999-12-02 | Compounds specific to adenosine A1 receptor and uses thereof |
| US09/454,075 US6686366B1 (en) | 1998-06-02 | 1999-12-02 | Compounds specific to adenosine A3 receptor and uses thereof |
| US09/454,075 | 1999-12-02 | ||
| PCT/US2000/032702 WO2001039777A1 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003519102A JP2003519102A (ja) | 2003-06-17 |
| JP2003519102A5 true JP2003519102A5 (enExample) | 2009-04-09 |
Family
ID=27412585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541509A Pending JP2003519102A (ja) | 1999-12-02 | 2000-12-01 | アデノシンａ▲下１▼、ａ▲下２ａ▼およびａ▲下３▼受容体に対して特異的な化合物並びにその使用 |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP1731520A1 (enExample) |
| JP (1) | JP2003519102A (enExample) |
| KR (1) | KR100840727B1 (enExample) |
| AT (1) | ATE335489T1 (enExample) |
| AU (1) | AU784878B2 (enExample) |
| CA (1) | CA2393179A1 (enExample) |
| CY (1) | CY1107653T1 (enExample) |
| DE (1) | DE60030002T2 (enExample) |
| DK (1) | DK1246623T3 (enExample) |
| ES (1) | ES2269217T3 (enExample) |
| HK (1) | HK1050319B (enExample) |
| IL (2) | IL149935A0 (enExample) |
| MX (1) | MXPA02005357A (enExample) |
| PT (1) | PT1246623E (enExample) |
| WO (1) | WO2001039777A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL204628B1 (pl) | 1998-06-02 | 2010-01-29 | Osi Pharmaceuticals | Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| NZ525885A (en) * | 2000-12-01 | 2005-01-28 | Osi Pharm Inc | Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities |
| UA74228C2 (uk) * | 2000-12-01 | 2005-11-15 | Осі Фармасьютікалз, Інк. | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ, СПЕЦИФІЧНІ ДО АДЕНОЗИНОВОГО A<sub>1</sub>, A<sub>2А</sub> І A<sub>3</sub> РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| ATE354573T1 (de) | 2000-12-21 | 2007-03-15 | Vertex Pharma | ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß |
| UA80258C2 (en) * | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
| DE10148883A1 (de) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
| CA2468673C (en) | 2001-11-30 | 2011-01-25 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 and a3 receptors and uses thereof |
| WO2003050241A2 (en) | 2001-12-12 | 2003-06-19 | The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services | Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
| DE60235500D1 (de) | 2001-12-20 | 2010-04-08 | Osi Pharm Inc | Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung |
| US20030229067A1 (en) | 2001-12-20 | 2003-12-11 | Arlindo Castelhano | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
| MXPA04005861A (es) * | 2001-12-20 | 2004-10-29 | Osi Pharm Inc | Compuestos antagonistas selectivos de pirrolopirimidina a2b, su sintesis y uso. |
| ATE434610T1 (de) | 2002-03-13 | 2009-07-15 | Euro Celtique Sa | Aryl substituierte pyrimidine und deren verwendung |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| CN1319968C (zh) | 2002-08-02 | 2007-06-06 | 沃泰克斯药物股份有限公司 | 用作gsk－3的抑制剂的吡唑组合物 |
| US7763627B2 (en) * | 2003-04-09 | 2010-07-27 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| AR043880A1 (es) * | 2003-04-22 | 2005-08-17 | Solvay Pharm Gmbh | Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas |
| WO2005004875A1 (ja) * | 2003-07-14 | 2005-01-20 | Sankyo Company, Limited | 経肺投与用医薬組成物 |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| WO2007111214A1 (ja) | 2006-03-27 | 2007-10-04 | Otsuka Chemical Co., Ltd. | トレハロース化合物および該化合物を含有する医薬 |
| EP2007373A4 (en) * | 2006-03-29 | 2012-12-19 | Foldrx Pharmaceuticals Inc | INHIBITION OF ALPHA SYNUCLEINE TOXICITY |
| TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
| EP2156833B1 (en) * | 2007-05-11 | 2011-11-30 | Santen Pharmaceutical Co., Ltd | Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient |
| WO2009052376A1 (en) | 2007-10-18 | 2009-04-23 | Musc Foundation For Research Development | Methods for the diagnosis of genitourinary cancer |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| PL2651417T3 (pl) | 2010-12-16 | 2017-08-31 | Calchan Limited | Pochodne pirolopirymidyny hamujące ASK1 |
| CA2873723A1 (en) * | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| GB201711234D0 (en) | 2017-07-12 | 2017-08-23 | Galapagos Nv | Pyrrolopyrimidine and pyrrolopyridine derivatives |
| KR20240018000A (ko) * | 2022-08-01 | 2024-02-13 | 주식회사 넥스트젠바이오사이언스 | A3 아데노신 수용체 작용제로서의 신규한 퓨린 유도체 화합물 |
| WO2024233605A1 (en) * | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3910913A (en) * | 1969-11-04 | 1975-10-07 | American Home Prod | 4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives |
| US5516894A (en) | 1992-03-11 | 1996-05-14 | The General Hospital Corporation | A2b -adenosine receptors |
| FI944602A0 (fi) | 1992-04-03 | 1994-10-03 | Upjohn Co | Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit |
| WO1995011681A1 (en) | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| US5780450A (en) | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| WO1997033879A1 (en) | 1996-03-15 | 1997-09-18 | Merck & Co., Inc. | Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor |
| JPH09291089A (ja) | 1996-04-26 | 1997-11-11 | Yamanouchi Pharmaceut Co Ltd | 新規な５−チアゾリルウラシル誘導体又はその塩 |
| US5786360A (en) | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
| AU8764398A (en) | 1997-07-29 | 1999-02-22 | Medco Research, Inc. | N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| PL204628B1 (pl) * | 1998-06-02 | 2010-01-29 | Osi Pharmaceuticals | Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne |
| US9816053B2 (en) | 2015-03-26 | 2017-11-14 | Melynda S DelCotto | Candle having a wooden wick with figured grain |
-
2000
- 2000-12-01 DK DK00988011T patent/DK1246623T3/da active
- 2000-12-01 EP EP06016543A patent/EP1731520A1/en not_active Withdrawn
- 2000-12-01 AT AT00988011T patent/ATE335489T1/de active
- 2000-12-01 HK HK03102257.1A patent/HK1050319B/en not_active IP Right Cessation
- 2000-12-01 CA CA002393179A patent/CA2393179A1/en not_active Abandoned
- 2000-12-01 JP JP2001541509A patent/JP2003519102A/ja active Pending
- 2000-12-01 WO PCT/US2000/032702 patent/WO2001039777A1/en not_active Ceased
- 2000-12-01 ES ES00988011T patent/ES2269217T3/es not_active Expired - Lifetime
- 2000-12-01 MX MXPA02005357A patent/MXPA02005357A/es active IP Right Grant
- 2000-12-01 PT PT00988011T patent/PT1246623E/pt unknown
- 2000-12-01 IL IL14993500A patent/IL149935A0/xx unknown
- 2000-12-01 EP EP00988011A patent/EP1246623B1/en not_active Expired - Lifetime
- 2000-12-01 DE DE60030002T patent/DE60030002T2/de not_active Expired - Lifetime
- 2000-12-01 KR KR1020027007039A patent/KR100840727B1/ko not_active Expired - Fee Related
- 2000-12-01 AU AU24270/01A patent/AU784878B2/en not_active Ceased
-
2006
- 2006-09-04 CY CY20061101246T patent/CY1107653T1/el unknown
-
2009
- 2009-07-15 IL IL199869A patent/IL199869A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003519102A5 (enExample) | ||
| US11730737B2 (en) | Aldose reductase inhibitors and uses thereof | |
| JP7688681B2 (ja) | アルドース還元酵素阻害剤およびその使用方法 | |
| CN103052637B (zh) | 醛糖还原酶抑制剂及其用途 | |
| CA2855759C (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
| CN105120866A (zh) | 与毒性醛相关的疾病和治疗 | |
| WO2009061681A2 (en) | Antagonists of pgd2 receptors | |
| JP2013056911A (ja) | 運動障害の予防および／または治療剤 | |
| AU2005215320A1 (en) | Amino alcohol compound | |
| JP2009500409A (ja) | 痛みを処置するためのα２アドレナリン作動剤 | |
| JPH01153689A (ja) | 抗パーキンソン病エルゴリン誘導体 | |
| JP2004517947A (ja) | そう痒状態の処置のためのｍｇｌｕｒ５アンタゴニストの使用 | |
| JP2005511639A (ja) | 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体 | |
| WO2016119570A1 (zh) | 尿酸性或痛风性疾病的预防或治疗 | |
| WO2024050434A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
| JP2001524546A (ja) | ベンゼンスルンアミド組成物 | |
| WO2008071869A2 (fr) | Utilisation de l'agomelatine pour le traitement de la leucomalacie periventriculaire | |
| JPH0653678B2 (ja) | アレルギ−性疾患治療剤 | |
| JP2023504547A (ja) | アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 | |
| TWI293027B (enExample) | ||
| JP2023505233A (ja) | アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 | |
| TW202019410A (zh) | 作為用於治療神經退化性疾病的ppargc1a活化劑的2-芳基苯并咪唑 | |
| WO2005105147A2 (en) | Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases | |
| MXPA06009610A (en) | Amino alcohol compound | |
| JPWO2001098300A1 (ja) | 神経変性疾患予防・治療薬 |